95494-51-2

Usage

Uses

Used in Pharmaceutical Research:
4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid (SALTDATA: FREE) is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activities. It may contribute to the development of novel drugs due to its unique chemical structure.
Used in Chemical Compound Design:
In the chemical industry, 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid (SALTDATA: FREE) is used as a building block for the creation of novel chemical compounds. Its incorporation into new molecules could lead to the discovery of innovative materials and therapeutic agents.
Further research is necessary to fully understand the capabilities and potential uses of 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid, as its precise properties and applications are still under investigation.

Upstream product

• 28144-70-9 anthranilic acid amide 
• 108-55-4 glutaric anhydride, 

Relevant academic research and scientific papers

Small molecular compound SPAM1 for up-regulating neuropeptide PACAP and receptor PAC1-R thereof and preparation method and application thereof

The invention discloses a small molecule compound SPAM1 for up-regulating neuropeptide PACAP and receptor PAC1-R thereof and a preparation method and application thereof. The structure of the small molecule compound SPAM1 is as shown in formula (I), and R = none or H20 or HCl; the SPAM1 is small in molecular weight, and can efficiently pass through biological barriers including a blood brain barrier, a blood testis barrier and the like; expression of neurotransmitter/conditioned PACAP secreted by hypothalamus-pituitary gland and a specific receptor PAC1-R of the neurotransmitter/conditioned PACAP acts on downstream glands of a gonad axis and an adrenal axis so that the regulation and control effects of the neurotransmitter/conditioned PACAP are comprehensive; the SPAM1 specifically targetsPAC1-R1, only acts on cells and tissues for naturally expressing a PAC1-R nervous system and an endocrine system, and is relatively small in side effect. Therefore, the SPAM1 will become a novel small-molecule compound medicine for effectively treating and preventing functional aging and disorder of the nervous system, the endocrine system and the immune system which are closely related to the neuropeptide PACAP.

ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase

The serine hydrolase monoacylglycerol lipase (MAGL) is involved in a plethora of pathological conditions, in particular pain and inflammation, various types of cancer, metabolic, neurological and cardiovascular disorders, and is therefore a promising target for drug development. Although a large number of irreversible-acting MAGL inhibitors have been discovered over the past years, there are only few compounds known so far which inhibit the enzyme in a reversible manner. Therefore, much effort is put into the development of novel chemical entities showing reversible inhibitory behavior, which is thought to cause less undesired side effects. To explore a wide range of chemical structures as MAGL binders, we have applied a virtual screening approach by docking small molecules into the crystal structure of human MAGL (hMAGL) and envisaged a library of 45 selected compounds which were then synthesized. Biochemical investigations included the determination of the inhibitory potency on hMAGL and two related hydrolases, i.e. human fatty acid amide hydrolase (hFAAH) and murine cholesterol esterase (mCEase). The most promising candidates from theses analyses, i.e. three ω-quinazolinonylalkyl aryl ureas bearing alkyl spacers of three to five methylene groups, exhibited IC50 values of 20–41 μM and reversible, detergent-insensitive behavior towards hMAGL. Among these compounds, the inhibitor 1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)butyl)urea (96) was selected for further kinetic characterization, yielding a dissociation constant Ki = 15.4 μM and a mixed-type inhibition with a pronounced competitive component (α = 8.94). This mode of inhibition was further supported by a docking experiment, which suggested that the inhibitor occupies the substrate binding pocket of hMAGL.

Synthesis and SAR studies of potent H+/K+-ATPase inhibitors of quinazolinone-Schiff's base analogues

A series of quinazolinone derived Schiff base derivatives 7–36 were synthesized and characterized by analytical and spectroscopic techniques. The synthesized analogues were screened for their in vitro H+/K+-ATPase inhibition. Most of the compounds showed excellent activity, compared to that of omeprazole, a reference drug. In particular, hydroxy and methoxy derivatives 13–24 were the most active compounds possessing a significant increase for different substituents on the benzene ring thus, contributing positively to gastric H+/K+-ATPase inhibition. Preliminary structure-activity relationship revealed that the compounds 13–24 with electron donating moiety (OH, OCH3) were found to be excellent activity and compounds 9–12 and 25–36 with electron withdrawing moiety (Cl, F, NO2 and Br) were found to be least antiulcer agents.

3-Propynyl-2-substituted carboxylic acid derivatives of quinazolinone

Alkylation of quinazolinone-2-carboxylic acids with propargyl bromide in dimethylformamide in the presence of potassium carbonate afforded 3-prop-2-ynyl quinazolinone-2-substituted carboxylic acid derivatives. Further reaction of 4b-c produced 5b-c, which indicates that N-alkylation occurs before esterification with a propynyl moiety.